CTXR – citius pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Form 8-K Citius Pharmaceuticals, For: Nov 15
Form 424B5 Citius Pharmaceuticals,
Form 8-K Citius Pharmaceuticals, For: Nov 06
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Mazur Leonard L
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Smith Robert Joseph
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.